174 related articles for article (PubMed ID: 25392210)
1. Specificity of coxsackievirus B3 interaction with human, but not murine, decay-accelerating factor: replacement of a single residue within short consensus repeat 2 prevents virus attachment.
Pan J; Zhang L; Organtini LJ; Hafenstein S; Bergelson JM
J Virol; 2015 Jan; 89(2):1324-8. PubMed ID: 25392210
[TBL] [Abstract][Full Text] [Related]
2. Variations of coxsackievirus B3 capsid primary structure, ligands, and stability are selected for in a coxsackievirus and adenovirus receptor-limited environment.
Carson SD; Chapman NM; Hafenstein S; Tracy S
J Virol; 2011 Apr; 85(7):3306-14. PubMed ID: 21270163
[TBL] [Abstract][Full Text] [Related]
3. Interaction of decay-accelerating factor with coxsackievirus B3.
Hafenstein S; Bowman VD; Chipman PR; Bator Kelly CM; Lin F; Medof ME; Rossmann MG
J Virol; 2007 Dec; 81(23):12927-35. PubMed ID: 17804498
[TBL] [Abstract][Full Text] [Related]
4. Interaction with coxsackievirus and adenovirus receptor, but not with decay-accelerating factor (DAF), induces A-particle formation in a DAF-binding coxsackievirus B3 isolate.
Milstone AM; Petrella J; Sanchez MD; Mahmud M; Whitbeck JC; Bergelson JM
J Virol; 2005 Jan; 79(1):655-60. PubMed ID: 15596863
[TBL] [Abstract][Full Text] [Related]
5. Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1.
Schmidtke M; Selinka HC; Heim A; Jahn B; Tonew M; Kandolf R; Stelzner A; Zell R
Virology; 2000 Sep; 275(1):77-88. PubMed ID: 11017789
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors.
Goodfellow IG; Evans DJ; Blom AM; Kerrigan D; Miners JS; Morgan BP; Spiller OB
J Virol; 2005 Sep; 79(18):12016-24. PubMed ID: 16140777
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of two coxsackievirus B3 strains: putative influence of virus-receptor interactions on pathogenesis.
Selinka HC; Wolde A; Pasch A; Klingel K; Schnorr JJ; Küpper JH; Lindberg AM; Kandolf R
J Med Virol; 2002 Jun; 67(2):224-33. PubMed ID: 11992583
[TBL] [Abstract][Full Text] [Related]
8. The crystal structure of a coxsackievirus B3-RD variant and a refined 9-angstrom cryo-electron microscopy reconstruction of the virus complexed with decay-accelerating factor (DAF) provide a new footprint of DAF on the virus surface.
Yoder JD; Cifuente JO; Pan J; Bergelson JM; Hafenstein S
J Virol; 2012 Dec; 86(23):12571-81. PubMed ID: 22973031
[TBL] [Abstract][Full Text] [Related]
9. Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor.
Martino TA; Petric M; Brown M; Aitken K; Gauntt CJ; Richardson CD; Chow LH; Liu PP
Virology; 1998 May; 244(2):302-14. PubMed ID: 9601501
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of differential receptor usage for naturally occurring CD55-binding and -nonbinding coxsackievirus B3 strains.
Wang Q; Yang Q; Liu C; Wang G; Song H; Shang G; Peng R; Qu X; Liu S; Cui Y; Wang P; Xu W; Zhao X; Qi J; Yang M; Gao GF
Proc Natl Acad Sci U S A; 2022 Jan; 119(4):. PubMed ID: 35046043
[TBL] [Abstract][Full Text] [Related]
11. Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection.
Zautner AE; Körner U; Henke A; Badorff C; Schmidtke M
J Virol; 2003 Sep; 77(18):10071-7. PubMed ID: 12941917
[TBL] [Abstract][Full Text] [Related]
12. Expression of human decay-accelerating factor on intestinal epithelium of transgenic mice does not facilitate infection by the enteral route.
Pan J; Zhang L; Odenwald MA; Shen L; Turner JR; Bergelson JM
J Virol; 2015 Apr; 89(8):4311-8. PubMed ID: 25653430
[TBL] [Abstract][Full Text] [Related]
13. Single amino acid changes in the virus capsid permit coxsackievirus B3 to bind decay-accelerating factor.
Pan J; Narayanan B; Shah S; Yoder JD; Cifuente JO; Hafenstein S; Bergelson JM
J Virol; 2011 Jul; 85(14):7436-43. PubMed ID: 21561916
[TBL] [Abstract][Full Text] [Related]
14. Enterovirus 70 receptor utilization is controlled by capsid residues that also regulate host range and cytopathogenicity.
Kim MS; Racaniello VR
J Virol; 2007 Aug; 81(16):8648-55. PubMed ID: 17537857
[TBL] [Abstract][Full Text] [Related]
15. A single amino acid substitution controls DAF-dependent phenotype of echovirus 11 in rhabdomyosarcoma cells.
Novoselov AV; Rezaykin AV; Sergeev AG; Fadeyev FA; Grigoryeva JV; Sokolova ZI
Virus Res; 2012 Jun; 166(1-2):87-96. PubMed ID: 22445689
[TBL] [Abstract][Full Text] [Related]
16. A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells.
Shafren DR; Williams DT; Barry RD
J Virol; 1997 Dec; 71(12):9844-8. PubMed ID: 9371658
[TBL] [Abstract][Full Text] [Related]
17. Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis.
Lim BK; Choi JH; Nam JH; Gil CO; Shin JO; Yun SH; Kim DK; Jeon ES
Cardiovasc Res; 2006 Aug; 71(3):517-26. PubMed ID: 16806133
[TBL] [Abstract][Full Text] [Related]
18. Virus-receptor interactions of coxsackie B viruses and their putative influence on cardiotropism.
Selinka HC; Wolde A; Sauter M; Kandolf R; Klingel K
Med Microbiol Immunol; 2004 May; 193(2-3):127-31. PubMed ID: 12920584
[TBL] [Abstract][Full Text] [Related]
19. Coxsackie B viruses that use human DAF as a receptor infect pig cells via pig CAR and do not use pig DAF.
Spiller OB; Goodfellow IG; Evans DJ; Hinchliffe SJ; Morgan BP
J Gen Virol; 2002 Jan; 83(Pt 1):45-52. PubMed ID: 11752699
[TBL] [Abstract][Full Text] [Related]
20. Characterization of echoviruses that bind decay accelerating factor (CD55): evidence that some haemagglutinating strains use more than one cellular receptor.
Powell RM; Schmitt V; Ward T; Goodfellow I; Evans DJ; Almond JW
J Gen Virol; 1998 Jul; 79 ( Pt 7)():1707-13. PubMed ID: 9680134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
